Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

1. Psychosis and schizophrenia

Psychosis and schizophrenia Psychosis and schizophrenia - NICE CKS Clinical Knowledge Summaries Share Psychosis and schizophrenia: Summary Psychosis is a disordered mental state characterized principally by positive symptoms such as hallucinations, delusions, and thought disorder. Psychotic symptoms are cardinal features of psychotic disorders such as schizophrenia, but may be caused by medicines and substance misuse, and by medical conditions such as sepsis in the elderly. Psychotic disorders (...) , including schizophrenia, are conditions in which psychosis occurs for a significant period of time. They may also be associated with negative symptoms (for example emotional blunting, reduced speech, loss of motivation, self neglect, and social withdrawal). With treatment, psychotic symptoms may resolve fully, recur intermittently with periods of remission between, or persist. Complications include: An increased risk of premature death due to an increased risk of suicide, cardiovascular disease

2015 NICE Clinical Knowledge Summaries

2. Canadian practice guidelines for comprehensive community treatment for schizophrenia and schizophrenia spectrum disorders (PubMed)

Canadian practice guidelines for comprehensive community treatment for schizophrenia and schizophrenia spectrum disorders The objective of this review is to identify the features and components of a comprehensive system of services for people living with schizophrenia. A comprehensive system was conceived as one that served the full range of people with schizophrenia and was designed with consideration of the incidence and prevalence of schizophrenia. The system should provide access (...) to the full range of evidence-based services, should be recovery oriented, and should provide patient-centred care.A systematic search was conducted for published guidelines for schizophrenia and schizophrenia spectrum disorders. The guidelines were rated by at least 2 raters, and recommendations adopted were primarily drawn from the National Institute for Clinical Excellence (2014) Guideline on Psychosis and Schizophrenia in adults and the Scottish Intercollegiate Guidelines Network guidelines

Full Text available with Trip Pro

2017 CPG Infobase

3. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. (PubMed)

Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels. For these people, a number of treatment strategies have emerged, including the prescription of a second anti-psychotic drug in combination with clozapine.To determine the clinical effects of various clozapine combination strategies with antipsychotic drugs in people (...) with treatment-resistant schizophrenia both in terms of efficacy and tolerability.We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (to 28 August 2015) and MEDLINE (November 2008). We checked the reference lists of all identified randomised controlled trials (RCT). For the first version of the review, we also contacted pharmaceutical companies to identify further trials.We included only RCTs recruiting people of both sexes, aged 18 years or more, with a diagnosis of treatment

Full Text available with Trip Pro

2017 Cochrane

4. Guidelines for the pharmacotherapy of schizophrenia in adults (PubMed)

Guidelines for the pharmacotherapy of schizophrenia in adults The present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains.Guidelines were developed using the ADAPTE process, which takes advantage of existing guidelines. Six guidelines were identified for adaptation, with recommendations extracted from each. For those specific to the pharmacotherapy of schizophrenia in adults, a working group selected between guidelines (...) and recommendations to create an adapted guideline.Recommendations can be categorized into 6 areas that include 1) first-episode schizophrenia, 2) acute exacerbation, 3) relapse prevention and maintenance treatment, 4) treatment-resistant schizophrenia, 5) clozapine-resistant schizophrenia, and 6) specific symptom domains. For each category, recommendations are made based on the available evidence, which is discussed and linked to other established guidelines.In most cases, evidence-based recommendations are made

Full Text available with Trip Pro

2017 CPG Infobase

5. Schizophrenia

Schizophrenia Evidence Maps - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading

2018 Trip Evidence Maps

6. Psychosis and schizophrenia in children and young people: recognition and management

Psychosis and schizophrenia in children and young people: recognition and management Psy Psychosis and schizophrenia in children chosis and schizophrenia in children and y and young people: recognition and oung people: recognition and management management Clinical guideline Published: 23 January 2013 nice.org.uk/guidance/cg155 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Psychosis and schizophrenia in children and young people: recognition and management (CG155) © NICE 2019. All rights reserved. Subject

2013 National Institute for Health and Clinical Excellence - Clinical Guidelines

7. Canadian schizophrenia guidelines: schizophrenia and other psychotic disorders with coexisting substance use disorders (PubMed)

Canadian schizophrenia guidelines: schizophrenia and other psychotic disorders with coexisting substance use disorders Persons with schizophrenia and other psychotic disorders frequently have coexisting substance use disorders that require modifications to treatment approaches for best outcomes. The objectives of this review were to identify evidence-based practices best practices that improve outcomes for individuals with schizophrenia and substance used disorders.We reviewed guidelines (...) that were published in the last 5 years and that included systematic reviews or meta-analyses. Most of our recommendations came from 2 publications from the National Institute for Health and Care Excellence (NICE): the 2011 guidance titled Coexisting Severe Mental Illness (Psychosis) and Substance Misuse: Assessment and Management in Healthcare Settings and the 2014 guidance titled Psychosis and Schizophrenia in Adults: Prevention and Management. We placed these recommendations into the Canadian context

Full Text available with Trip Pro

2017 CPG Infobase

8. Canadian treatment guidelines on psychosocial treatment of schizophrenia in adults (PubMed)

Canadian treatment guidelines on psychosocial treatment of schizophrenia in adults It is generally recognised that psychosocial interventions are essential components of the effective treatment of schizophrenia in adults. A considerable body of research is being published regarding the effectiveness of such interventions. In the current article, we derive recommendations reflecting the current state of evidence for their effectiveness.Recommendations were formulated on the basis of a review (...) be provided with education about the nature of schizophrenia and its treatment. Several recent innovative psychosocial approaches to treatment are awaiting more thorough evaluation.There continues to be strong evidence for the effectiveness of several psychosocial interventions in improving outcomes for adults with schizophrenia. In the past decade, innovative interventions have been described, several of which are the subject of ongoing evaluative research.

Full Text available with Trip Pro

2017 CPG Infobase

9. Psychosis and schizophrenia in adults: prevention and management

Psychosis and schizophrenia in adults: prevention and management Psy Psychosis and schizophrenia in adults: chosis and schizophrenia in adults: pre prev vention and management ention and management Clinical guideline Published: 12 February 2014 nice.org.uk/guidance/cg178 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view (...) in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Psychosis and schizophrenia in adults: prevention and management (CG178) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions

2014 National Institute for Health and Clinical Excellence - Clinical Guidelines

10. Canadian guidelines for the pharmacological treatment of schizophrenia spectrum and other psychotic disorders in children and youth (PubMed)

Canadian guidelines for the pharmacological treatment of schizophrenia spectrum and other psychotic disorders in children and youth Schizophrenia spectrum and other psychotic disorders often have their onset in adolescence. The sequelae of these illnesses can negatively alter the trajectory of emotional, cognitive, and social development in children and youth if left untreated. Early and appropriate interventions can improve outcomes. This article aims to identify best practices (...) in the pharmacotherapy management of children and youth with schizophrenia spectrum disorders.A systematic search was conducted for published guidelines for schizophrenia and schizophrenia spectrum disorders in children and youth (under age 18 years). Recommendations were drawn from the National Institute for Health and Care Excellence guidelines on psychosis and schizophrenia in children and youth (2013 and 2015 updates). Current guidelines were adopted using the ADAPTE process, which includes consensus ratings

Full Text available with Trip Pro

2017 CPG Infobase

11. Schizophrenia (revised)

Schizophrenia (revised) AACAP OFFICIAL ACTION Practice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia Jon McClellan, M.D., Saundra Stock, M.D., ANDthe American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI) This Practice Parameter reviews the literature on the assessment and treatment of children and adolescentswithschizophrenia.Early-onsetschizophreniaisdiagnosedusingthesamecriteriaasin (...) sideeffects.Furtherresearchisneededtodevelopmoreeffectiveandsafertreatments. J.Am.Acad. ChildAdolesc.Psychiatry,2013;52(9):976–990. Key Words: schizophrenia, psychosis S chizophreniaportendssubstantialmorbidity and suffering to those af?icted and their families. Schizophrenia spectrum disorders often?rstpresentduringadolescenceandrarelyin childhood.SincethelastPracticeParameterforthe Assessment and Treatment of Children and Adolescents with Schizophrenia was published, 1 knowledge of this topic has increased substan- tially.Thisrevisedversionoftheparameterpresents

2013 American Academy of Child and Adolescent Psychiatry

12. Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review

Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review | CADTH.ca Find the information you need Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review Published on: August 23, 2012 (...) Product Line: , CADTH Technology Overviews Issue: Volume 2, Issue 3 Result type: Report Adapted from [CADTH Optimal Use Report; Volume 1, Issue 1B]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2011. For more information on this project, visit Introduction Schizophrenia is a mental illness that requires lifelong treatment 1 and is associated with symptoms that include hallucinations, delusions, cognitive impairment, disorganized thoughts, social withdrawal, and low motivation. 2

2015 CADTH - Health Technology Assessment

13. Canadian guidelines for the assessment and diagnosis of patients with schizophrenia spectrum and other psychotic disorders (PubMed)

Canadian guidelines for the assessment and diagnosis of patients with schizophrenia spectrum and other psychotic disorders The objective of this article is to identify best practices in the diagnosis and assessment of patients with schizophrenia spectrum and other psychotic disorders. The diagnosis and assessment may occur in a range of situations from the emergency room to the outpatient clinic and at different stages of the disorder. The focus may be on acute exacerbations of illness (...) , residual symptoms, levels of function, or changes in the response to treatment.A systematic search was conducted for guidelines published in the last 5 years for schizophrenia and schizophrenia spectrum disorders. The guidelines were rated by at least 2 raters, and recommendations adopted on the diagnosis and assessment were primarily drawn from the American Psychiatric Association practice guidelines for the psychiatric evaluation of adults and the National Institute for Health and Care Excellence

Full Text available with Trip Pro

2017 CPG Infobase

14. Transcranial Magnetic Stimulation for Major Depression and Schizophrenia

Transcranial Magnetic Stimulation for Major Depression and Schizophrenia Transcranial Magnetic Stimulation for Major Depression and Schizophrenia An Evidence Check rapid review brokered by the Sax Institute for the NSW Ministry of Health. August 2017 An Evidence Check rapid review brokered by the Sax Institute for the NSW Ministry of Health. August 2017. This report was prepared by: Ma N, Atukorale Y, Duncan J, Marlow N, Cameron A Research and Evaluation, incorporating ASERNIP-S, Royal (...) www.saxinstitute.org.au knowledge.exchange@saxinstitute.org.au Phone: +61 2 91889500 Suggested Citation: Ma N, Atukorale Y, Marlow N, Duncan J, Cameron A (2017) Transcranial Magnetic Stimulation for major depression and schizophrenia: an Evidence Check brokered by the Sax Institute (www.saxinstitute.org.au) for the NSW Ministry of Health, 2017. Disclaimer: This Evidence Check Review was produced using the Evidence Check methodology in response to specific questions from the commissioning agency. It is not necessarily

2018 Sax Institute Evidence Check

15. Occupational therapy delivered by specialists versus non-specialists for people with schizophrenia. (PubMed)

Occupational therapy delivered by specialists versus non-specialists for people with schizophrenia. Schizophrenia is a severe mental health condition that is characterised by positive symptoms, such as hallucinations and delusions; negative symptoms, such as flattened affect, thought disorder (disrupted speech), and lack of motivation; and cognitive symptoms, such as problems with memory and attention. Schizophrenia can occur as an isolated episode, or as a recurring cycle of remission (...) and relapse, and is associated with impairment in psychosocial and occupational functioning.Although antipsychotic drugs are the main treatment for people with schizophrenia, in most countries mental health services usually provide a range of add-on interventions, including occupational therapy. This is a complex intervention designed to support and enable continued participation in daily life through engagement in activities and occupations meaningful to the individual. Occupational therapists

2018 Cochrane

16. Schizophrenia (Treatment)

Schizophrenia (Treatment) Schizophrenia Treatment & Management: Approach Considerations, Antipsychotic Pharmacotherapy, Other Pharmacotherapy Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjg4MjU5LXRyZWF0bWVudA (...) == processing > Schizophrenia Treatment & Management Updated: Mar 16, 2018 Author: Frances R Frankenburg, MD; Chief Editor: Glen L Xiong, MD Share Email Print Feedback Close Sections Sections Schizophrenia Treatment Approach Considerations Treatment of schizophrenia requires integration of medical, psychological, and psychosocial inputs. The bulk of care occurs in an outpatient setting and probably is best carried out by a multidisciplinary team, including some combination of the following

2014 eMedicine.com

17. Schizophrenia (Follow-up)

Schizophrenia (Follow-up) Schizophrenia Treatment & Management: Approach Considerations, Antipsychotic Pharmacotherapy, Other Pharmacotherapy Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjg4MjU5LXRyZWF0bWVudA (...) == processing > Schizophrenia Treatment & Management Updated: Mar 16, 2018 Author: Frances R Frankenburg, MD; Chief Editor: Glen L Xiong, MD Share Email Print Feedback Close Sections Sections Schizophrenia Treatment Approach Considerations Treatment of schizophrenia requires integration of medical, psychological, and psychosocial inputs. The bulk of care occurs in an outpatient setting and probably is best carried out by a multidisciplinary team, including some combination of the following

2014 eMedicine.com

18. Horticultural therapy for schizophrenia. (PubMed)

Horticultural therapy for schizophrenia. Horticultural therapy is defined as the process of utilising fruits, vegetables, flowers and plants facilitated by a trained therapist or healthcare provider, to achieve specific treatment goals or to simply improve a person's well-being. It can be used for therapy or rehabilitation programs for cognitive, physical, social, emotional, and recreational benefits, thus improving the person's body, mind and spirit. Between 5% to 15% of people (...) with schizophrenia continue to experience symptoms in spite of medication, and may also develop undesirable adverse effects, horticultural therapy may be of value for these people.To evaluate the effects of horticultural therapy for people with schizophrenia or schizophrenia-like illnesses compared with standard care or other additional psychosocial interventions.We searched the Cochrane Schizophrenia Group Trials Register (Janurary 2013) and supplemented this by contacting relevant study authors, and manually

Full Text available with Trip Pro

2014 Cochrane

19. Canadian treatment guidelines on psychosocial treatment of schizophrenia in children and youth (PubMed)

Canadian treatment guidelines on psychosocial treatment of schizophrenia in children and youth A panel of experts, including researchers, clinicians and people with lived experience, was brought together to develop the new Canadian schizophrenia guidelines for the psychosocial treatment of children and youth with schizophrenia or psychotic disorders.The ADAPTE process, which relies on adapting existing high-quality guidelines, was used. Existing guidelines for children and youth (mostly from (...) treatment of children and youth with schizophrenia or psychotic disorders report evidence-based treatments as well as important considerations for providers who work with this clientele. More studies with children and youth with schizophrenia and psychotic disorders are warranted. If followed, these guidelines should facilitate the recovery of children and youth with schizophrenia or psychotic disorders as well as the recovery of their families.

Full Text available with Trip Pro

2017 CPG Infobase

20. National clinical guideline for the treatment of patients with schizophrenia and complex treatment courses

National clinical guideline for the treatment of patients with schizophrenia and complex treatment courses NATIONAL CLINICAL GUIDELINE FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA AND COMPLEX TREATMENT COURSES – PERSISTENT SYMPTOMS, ABUSE OR LOSS OF CONTACT WITH TREATMENT SERVICES Quick guide National clinical guideline for the treatment of patients with schizophrenia and complex treatment courses. Published by the Danish Health Authority, March 2016 Pharmacological treatment v In patients (...) with schizophrenia undergoing treatment with clozapine, it is good practice to adjust the dose according to clinical response and adverse reactions. The upper limit of the recommended therapeutic range may be exceeded, but such a choice should always lead to considerations about reducing the dose to minimise adverse reactions. ? Consider injection with long-acting antipsychotic in patients with schizophrenia with irregular medicine intake and persistent psychotic symptoms ( ? ???). ? SSRI products should only

2016 Danish National Clinical Guidelines